Reinstating anti-tumor activity of Natural Killer cells

2019 ◽  
Vol 19 (10) ◽  
pp. e158
Author(s):  
Ceyda Caliskan ◽  
Michael Chrobok ◽  
Arnika Kathleen Wagner ◽  
Johanna Borg Bruchfeld ◽  
Hareth Nahi ◽  
...  
2018 ◽  
Vol 7 (6) ◽  
pp. e1431085 ◽  
Author(s):  
Xinxin Li ◽  
Wenjuan Dong ◽  
Ansel P. Nalin ◽  
Yufeng Wang ◽  
Pan Pan ◽  
...  

2010 ◽  
Vol 51 (7) ◽  
pp. 1293-1304 ◽  
Author(s):  
William M. Siders ◽  
Jacqueline Shields ◽  
Carrie Garron ◽  
Yanping Hu ◽  
Paula Boutin ◽  
...  

2020 ◽  
Author(s):  
Marco Stringhini ◽  
Jacqueline Mock ◽  
Vanessa Fontana ◽  
Patrizia Murer ◽  
Dario Neri

AbstractBackgroundLIGHT is a member of the TNF superfamily, which has been claimed to mediate anti-tumor activity on the basis of cancer cures observed in immunocompetent mice bearing transgenic LIGHT-expressing tumors. The preclinical development of a LIGHT-based therapeutic has been hindered by the lack of functional stability exhibited by this protein.MethodsHere, we describe the cloning, expression and characterization of five antibody-LIGHT fusion proteins, directed against the alternatively-spliced EDA domain of fibronectin, a conserved tumor-associated antigen.ResultsAmong the five tested formats, only the sequential fusion of the F8 antibody in single-chain diabody format, followed by the LIGHT homotrimer expressed as a single polypeptide, yielded a protein (termed “F8-LIGHT”) which was not prone to aggregation. A quantitative biodistribution analysis in tumor bearing mice, using radioiodinated protein preparations, confirmed that F8-LIGHT was able to preferentially accumulate at the tumor site, with a tumor-to-blood ratio of ca. five to one twenty-four hours after intravenous administration. Tumor therapy experiments, performed in two murine tumor models (CT26 and WEHI-164), featuring different levels of lymphocyte infiltration into the neoplastic mass, revealed that F8-LiGHT could significantly reduce tumor cell growth and was more potent than a similar fusion protein (KSF-LIGHT), directed against hen egg lysozyme and serving as negative control of irrelevant specificity in the mouse. At a mechanistic level, the activity of F8-LiGHT was mainly due to an intratumoral expansion of Natural Killer cells, whereas there was no evidence of expansion of CD8+ T cells, neither in the tumor, nor in draining lymph nodes.ConclusionWe developed a novel recombinant LIGHT fusion protein, able to accumulate at the site of disease and which displayed anti-tumor activity in two mouse models of cancer.


1998 ◽  
Vol 89 (4) ◽  
pp. 427-435
Author(s):  
Mitsuomi Hirashima ◽  
Naoko Yoshida ◽  
Masako Seki ◽  
Hiroki Okada ◽  
Seishi Takamura ◽  
...  

2013 ◽  
Vol 134 (12) ◽  
pp. 2829-2840 ◽  
Author(s):  
Achim Rothe ◽  
Ron D. Jachimowicz ◽  
Sven Borchmann ◽  
Marie Madlener ◽  
Jörg Keßler ◽  
...  

2019 ◽  
Vol 33 (2) ◽  
pp. 229-243
Author(s):  
Jamilya Saparbay ◽  
Yuka Tanaka ◽  
Naoki Tanimine ◽  
Masahiro Ohira ◽  
Hideki Ohdan

Sign in / Sign up

Export Citation Format

Share Document